Odyssey Health Secures Exclusive Global Rights for BreastCheck™: Strategic Move Set to Drive Near-Term Revenue Growth

LAS VEGAS, NV, April 22, 2026 — Odyssey Health, Inc. (OTCQB: ODYY), a company specializing in life-saving medical device technologies, has announced a transformative milestone: the closing of a definitive sub-license agreement that grants its wholly-owned subsidiary, Odyssey Medical Devices, Inc., exclusive worldwide marketing and distribution rights for BreastCheck™.

Key Points for Investors

• Exclusive Global Rights Acquired: Odyssey now holds the sole distribution and marketing rights for BreastCheck™ across the globe, positioning itself as a major player in the \$26 billion breast cancer screening market.
• Commercial Launch and Recurring Revenue: The agreement is expected to enable Odyssey to generate near-term revenue, with commercial sales of BreastCheck™ anticipated to begin in the second half of 2026.
• Differentiated Product Offering: BreastCheck™ is a non-invasive, at-home screening solution that delivers results in approximately 15 minutes. The product is designed as a first-line screening tool to increase accessibility and frequency of breast cancer screening, potentially expanding patient engagement and recurring usage.
• Regulatory Approvals: BreastCheck™ is registered with the U.S. Food and Drug Administration (FDA), as well as with regulatory bodies in the European Union and United Kingdom, enabling a broad commercial launch.
• Strategic Shift: This acquisition signifies Odyssey Health’s strategic transition toward revenue-generating, commercial-stage products with recurring revenue potential, strengthening the company’s long-term growth prospects.

Product Details and Market Opportunity

BreastCheck™, developed by Davion Healthcare PLC, is an FDA-registered, low-cost, and accurate device for routine monitoring of breast abnormalities. The device works by averaging temperature at three areas on each breast. Users then compare corresponding areas between breasts and enter the data into the BreastCheck™ Mobile App, which interprets the results immediately. This approach is intended to complement established screening procedures such as clinical breast exams and mammography, not to replace them.

The global breast cancer screening market is estimated at approximately \$26 billion. Breast cancer remains the most common cancer among women and a leading cause of cancer-related deaths. In the U.S. alone, more than 376,000 cases (invasive and non-invasive) are projected in 2025. Globally, the number of new breast cancer cases is expected to rise to 3.2 million annually by 2050, underscoring the significant and growing need for accessible screening solutions.

Potential Shareholder Impact and Price Sensitivity

• Near-Term Revenue Generation: The commercial launch of BreastCheck™ in the second half of the year could provide the company with immediate revenue streams, a critical milestone for any medical device company transitioning from development to commercialization.
• Recurring Revenue Model: As an at-home, repeat-use screening tool, BreastCheck™ could generate consistent and predictable revenue, enhancing Odyssey Health’s financial stability and growth outlook.
• Global Market Access: With regulatory approvals in major markets, Odyssey is well-positioned for rapid international expansion, which may further boost revenue and market share.

Risks and Forward-Looking Statements

Investors should note that the company’s future performance will depend on its ability to successfully manufacture, market, and distribute BreastCheck™ within expected timelines. The company also highlights the need for adequate financing (dilutive or non-dilutive) and the successful realization of the anticipated benefits, safety, and effectiveness of BreastCheck™. Broader economic and market factors may also impact outcomes.

All forward-looking statements in the company’s communication are subject to risks and uncertainties that may cause actual results to differ materially from expectations.

About Odyssey Health, Inc.

Odyssey Health, Inc. is a medical technology company focused on creating, acquiring, and accumulating assets with technological advantages and substantial market opportunities. Its mission is to deliver distinct and meaningful medical solutions that address critical healthcare needs.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors are encouraged to conduct their own research and consult with professional advisors before making any investment decisions. The article contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied.

View Odyssey Health, Inc. Historical chart here